Ajanta Pharma Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹45.5K Cr
The provided document is a cover letter for the earnings call transcript dated 30th July 2026; it does not contain detailed discussions or statements on future growth expectations in sales, revenue, or volumes. The provided document is a cover letter regarding the written transcript of Ajanta Pharma’s earnings call held on 30th July 2026.
From Ajanta Pharma Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹3,561
Market Cap
₹45.5K Cr
P/E Ratio
40.1
How does Ajanta Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare Ajanta Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Ajanta Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.4K Cr, net profit ₹267 Cr.
Full financials →📊 Revenue & Sales Performance
📈 Profitability & Margins
🏗️ Capital Expenditure Plans
💰 Fundraising & Capital Structure
- →The provided transcript page does not mention any current or future fundraising plans through debt or equity.
- →It solely contains a formal communication about uploading the earnings call transcript dated 30th July 2026.
- →No information on fundraising activities or intentions is included on this page.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Ajanta Pharma Ltd Q1 FY27 results?
The provided document is a cover letter for the earnings call transcript dated 30th July 2026; it does not contain detailed discussions or statements on future growth expectations in sales, revenue, or volumes. The provided document is a cover letter regarding the written transcript of Ajanta Pharma’s earnings call held on 30th July 2026.
What is Ajanta Pharma Ltd share price analysis?
Ajanta Pharma Ltd currently shows a neutral. The stock trades at a P/E of 40.1 with a market cap of ₹45,483 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ajanta Pharma Ltd planning capital expenditure?
The provided document is a cover letter for the written transcript of Ajanta Pharma's earnings call held on 30th July 2026.
Keep Ajanta Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.